Skip to content
All compound profiles

EVIDENCE PROFILE / PUBLISHED

VIP (vasoactive intestinal peptide)

VIP is a 28-amino-acid neuropeptide; aviptadil is the name used for its synthetic form. Health Canada Drug Product Database searches found no aviptadil product, and a large randomized trial of intravenous aviptadil in critical COVID-19 found no significant improvement in day-90 outcomes.

Aliases reviewed
Vasoactive intestinal peptide, Vasoactive intestinal polypeptide
Sources checked
2026-10-27
Editorial status
published

Evidence at a glance

Human
LimitedOne disease-specific randomized placebo-controlled trial of intravenous synthetic VIP was reviewed.
Animal/cell
Not rated
Approved medicine
Not rated

Summarises how much research the profile's sources report, and of what kind. It is not a verdict on the compound or on any catalogue material.

PREPPY BOY ASKS

“A familiar name can hide a different molecule, fragment, formulation, or evidence story.”

The catalogue name is a starting point, not proof of formulation or identity. This concise profile was researched from primary and regulatory records; supplier listings were used only to find the name.

Identity

VIP (vasoactive intestinal peptide or polypeptide) is a 28-amino-acid neuropeptide. UniProt P01282 gives the human sequence HSDAVFTDNYTRLRKQMAVKKYLNSILN with a C-terminal asparagine amide, cut from a precursor that also yields the separate peptides PHM-27 and PHV-42. TESICO investigators describe aviptadil as the synthetic form of VIP; fragments, analogues and combination products are different materials.

Biological mechanism or research interest

UniProt summarizes VIP as acting through the VIP receptors VPR1 and VPR2, with roles in vasodilation, smooth-muscle relaxation, neuroprotection and immune modulation. These functional statements are curated summaries of laboratory studies that were not opened individually here. TESICO investigators studied synthetic VIP on the hypothesis that it protects the lungs in acute hypoxaemic respiratory failure.

Verified approved human uses

Health Canada Drug Product Database active-ingredient searches for aviptadil and vasoactive returned no records on 2026-10-27. A search for VIP returned only an unrelated radiopharmaceutical, lutetium (177Lu) vipivotide tetraxetan. In Wales, a June 2017 All Wales Medicines Strategy Group appraisal (last reviewed September 2020) recommends Invicorp, a fixed combination of aviptadil with phentolamine mesilate, as a solution for injection within NHS Wales for erectile dysfunction in adult males whose condition has not responded to oral PDE5 inhibitors. The appraisal is not a marketing-authorisation record, and that combination medicine does not establish any use for VIP alone or for a catalogue material.

Investigational human evidence

TESICO, an NIH-funded randomized placebo-controlled trial at 28 U.S. sites, gave intravenous aviptadil (231 participants) or placebo (230) to hospitalised adults with COVID-19-associated acute hypoxaemic respiratory failure. Most participants (95%) were also prescribed glucocorticoids, and some were also randomized to remdesivir or placebo in a 2x2 factorial design. The trial was stopped for futility and showed no significant improvement in the day-90 recovery outcome or in mortality. An earlier phase 2/3 randomized trial cited by the investigators was not reviewed here.

The reviewed evidence does not show respiratory, immune, anti-inflammatory or general wellness benefit, and the largest trial reviewed found no significant improvement in day-90 recovery or mortality in critical COVID-19. The receptor and vasodilation roles that UniProt summarizes describe endogenous VIP biology, not demonstrated effects of a catalogue material. The NHS Wales erectile-dysfunction recommendation covers one specific combination medicine, not VIP on its own.

Human versus animal or cell evidence

A 1982 study isolated human VIP from colonic tissue and found its amino acid composition and N-terminal histidine identical to bovine and porcine VIP. It is a chemistry study with no biological outcome measures. The receptor and vasodilation findings that UniProt summarizes come from laboratory studies that this review did not open individually.

Limitations and known risks

In TESICO, hypotension, diarrhoea and facial flushing were the most common and prominent infusion-associated events. A composite safety outcome up to day 5 (death, serious adverse events, organ failure, serious infection or grade 3-4 adverse events) occurred in 63% of aviptadil and 56% of placebo participants, a difference that was not statistically significant. The identity, purity and quality of a catalogue material are unverified, and the reviewed sources do not address fragments, analogues or non-pharmaceutical preparations.

What this profile is—and is not

Concise source review from primary and regulatory records, independently checked for source accuracy; supplier listings were used only to find the name. Recheck before material revision.

This is sourced education, not medical advice or a personal-use recommendation. It does not validate the identity, purity, sterility, safety, or effectiveness of a catalogue material.